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Background: Although data on the inverse association between colorectal adenomas (CRA) and daily
aspirin or statin therapy exists in white and black patients, scarce data exists on these associations in the
Hispanic population. With a rapidly increasing Hispanic population in the United States, defining the
association in Hispanics is crucial.
Methods: The study sample included 1,843 consecutive patients who underwent a colonoscopy (screening
or diagnostic) from 2009 to 2011 at a community hospital in East Meadow, New York. Data was then
extracted from patient charts regarding aspirin and/or statin use. Adjusted odds ratios (OR) and their 95%
confidence intervals (CI) were calculated to assess the association between colonoscopy findings and aspirin,
statin, or aspirin/statin use.
Results: In our total population including all races, aspirin user had an increased risk for having two or
more adenomas (OR =1.73, 95% CI: 1.00, 2.99, P=0.05) and presence of an adenoma in the proximal colon
(OR =1.66, 95% CI: 1.07, 2.58, P=0.02). In the total study population, those who used both statin and
aspirin had an increased risk for having two or more adenomas (OR =2.56, 95% CI: 1.21, 5.39, P=0.01). In
the Hispanic population, users of both medications had an increased risk for having two or more adenomas
(OR =19.04, 95% CI: 1.30, 280.09, P=0.03), adenoma present in the distal colon (OR =5.75, 95% CI: 1.64,
20.21, P=0.01) and largest adenoma in distal colon (OR =5.75, 95% CI: 1.64, 20.21, P=0.01).
Conclusions: Aspirin use and aspirin/statin use was associated with abnormal colonoscopy findings, particularly
in the Hispanic population. These findings may be due to environmental factors such as dietary, colonic flora, or
genetic susceptibility. The findings warrant further investigational research, particularly in Hispanics.
Keywords: Colorectal adenomas (CRA); Hispanic; aspirin; statin
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Introduction
Colorectal adenocarcinoma is the third most common
cancer and the third leading cause of cancer-related deaths
in both men and woman. In 2011, there were 141,210 new
cases of colorectal cancer and 49,380 colorectal cancer-
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related deaths. It is estimated that a previous colorectal
adenocarcinoma diagnosis was present in almost 1.2 million
men and women living in the U.S. as of January 1, 2012,
with 1- and 5-year relative survival rates of 83% and
64%, respectively (1). One of the unique aspects of colon
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cancer is that most arise from pre-malignant adenomas
in an adenoma-carcinoma sequence. Initially, the colonic
mucosa undergoes chromosomal mutations involving genes
such as APC, k-ras and DCC, among others. The mucosa
then proliferates into an adenoma and after additional
mutations in genes such as p53, the adenoma transforms
in a carcinoma (2). Since most colorectal cancers follow this
adenoma-carcinoma time sequence, colonoscopy has become
an intervention to detect and remove colorectal adenomas
(CRA) before they become cancerous. While the use of
screening tests prevention of colorectal cancer or detection
and at an earlier stage is recommended, only 59% of men and
women 50 years of age and older receive colorectal cancer
screening according to published guidelines. Less than 40%
of these cases are diagnosed at a local stage when treatment
has a higher success rate. The benefits of early detection are
documented in the medical literature. One study showed that
colonic polypectomy through colonoscopy reduced colon
cancer mortality by 53% (3).
In comparison to whites, all other racial and ethnic
groups are less likely to be diagnosed with colorectal
cancer at an early stage when treatment is more successful.
Whether this discrepancy is due to true difference between
these groups or is secondary to lack of access of care remains
undetermined. Epidemiological studies that assess this
discrepancy are crucial to determining the true nature of
this racial disparity. According to the U.S. Census Bureau,
Hispanics currently comprise 17% of the United States
population at 53 million, and is projected to grow to 31% of
the U.S. population by 2060 to an estimated 128.8 million
people (4). In the US, Hispanics are the largest and fastest
growing minority group. In the total Hispanic population,
the incidence of colorectal cancer is 46.9 per 100,000 with a
mortality of 15.3 per 100,000 (1).
Aspirin and statins may both reduce the incidence
of colorectal cancer (5). Although data on the inverse
association of daily aspirin and statin therapy exists in white
and black patients, scarce data exists on their effect on
the incidence of CRA in the Hispanic patient population.
In this study we assessed whether reported use of these
medications was associated with the incidence of CRA in
our multi-racial hospital.
Methods
Patients
Following Institutional Review Board (IRB) approval at
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Nassau University Medical Center, a 530-bed tertiary
care teaching hospital in East Meadow, New York, a
retrospective chart review was performed between July 1,
2009 and March 21, 2011. We established a database
of 1,843 patients undergoing screening or diagnostic
colonoscopy. Only patients with listed medications were
used for analysis. Patients with colon cancer, inflammatory
bowel disease, or incomplete colonoscopies were excluded
from this study. A total of 1,495 patients were included in
the analysis on statin use, 1,038 patients were included in
the analysis on aspirin use and 672 patients were included
in the analysis of use of both statin and aspirin. Data were
collected on patient demographics and potential risk factors
for adenoma including age, sex, race, body mass index
(BMI), diabetes, hypertension, smoking, alcohol, and family
history of colorectal cancer along with aspirin and/or statin
use. Recorded colonoscopy findings included presence
of adenoma, adenoma ≥10 mm, two or more adenomas,
adenoma present in proximal colon, adenoma present in
distal colon, largest adenoma in the proximal colon and
largest adenoma in the distal colon.
Statistical analysis
Comparisons between categorical variables were made
using a chi square test and a t-test was used for comparisons
between continuous variables. Unconditional logistic
regression was used to generate age-, gender-and raceadjusted odds ratios and their 95% confidence intervals
(CI) comparing medication users with non-users. Statistical
analyses were performed with SAS 9.3 software.
Results
Table 1 shows the demographic characteristics of statin users
and non-users. The mean age was higher among statin
users than non-users (59.6 vs. 54.4, P<0.0001). A larger
proportion of the statin users (58.3%, n=229) vs. nonusers (48.1%, n=529) were female (P=0.0005). Users and
non-users also differed in their racial breakdown (P=0.01),
all metabolic and environmental factors including BMI
(P<0.0001), presence of diabetes (P<0.0001), hypertension
(P<0.0001), smoking status (P=0.03) and alcohol use
(P=0.04). Statin users and non-users did not differ in
their family history of colorectal cancer. Table 2 shows the
association between statin use and colonoscopy findings,
adjusted for age, sex, race, BMI, diabetes, hypertension and
smoking or alcohol use. No associations were seen between
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Table 1 Demographics of statin users and non-users undergoing colonoscopy
Non statin user (n=1,102)

Statin user (n=393)

P value*

54.4±14.9

59.6±9.6

<0.0001

Age
Sex—female

529 (48.1%)

229 (58.3%)

0.0005

Race (%)

0.01

White

248 (22.5)

64 (16.3)

Black

380 (34.5)

153 (39.0)

Hispanic

429 (39.0)

149 (38.0)

44 (4.0)

26 (6.6)

Other
BMI

28.5±5.9

30.0±6.3

<0.0001

Diabetes—yes

165 (15.0%)

166 (42.2%)

<0.0001

Hypertension—yes

472 (42.8%)

276 (70.2%)

<0.0001

Smoking—yes

288 (26.1%)

81 (20.6%)

0.03

Alcohol—yes

209 (19.0%)

56 (14.3%)

0.04

82 (7.4%)

23 (5.9%)

0.48

Family history of colorectal cancer

*, t-test used for continuous variables and chi square test used for categorical variables. BMI, body mass index.

Table 2 Association between statin use and colonoscopy findings in total population and Hispanics
Total population

Adenoma

No statin use

Statin use

Statin use vs. no

(n=1,102, %)

(n=393, %) use OR (95% CI)*

Hispanics
P value

No statin use

Statin use

Statin use vs. no

(n=429, %)

(n=149, %)

use OR (95% CI)*

P value

216 (19.6)

82 (20.9)

1.01 (0.74, 1.38)

0.96

65 (15.2)

24 (16.1)

1.05 (0.60, 1.83)

0.87

Adenoma ≥10 mm

39 (3.5)

12 (3.1)

0.76 (0.37, 1.57)

0.46

10 (2.3)

2 (1.3)

0.59 (0.11, 3.27)

0.54

Two or more

67 (6.1)

34 (8.7)

1.32 (0.83, 2.10)

0.25

17 (4.0)

9 (6.0)

1.44 (0.57, 3.61)

0.44

121 (11.0)

50 (12.7)

1.10 (0.75, 1.61)

0.63

28 (6.5)

11 (7.4)

1.14 (0.52, 2.52)

0.74

122 (11.1)

44 (11.2)

0.92 (0.62, 1.36)

0.66

42 (9.8)

18 (12.1)

1.26 (0.66, 2.40)

0.48

110 (10.0)

41 (10.4)

1.01 (0.67, 1.52)

0.96

25 (5.8)

9 (6.0)

0.95 (0.40, 2.25)

0.90

114 (10.3)

42 (10.7)

0.96 (0.64, 1.44)

0.84

41 (9.6)

17 (11.4)

1.28 (0.67, 2.47)

0.45

adenomas
Adenoma present
in proximal colon
Adenoma present
in distal colon
Largest adenoma
in proximal colon
Largest adenoma
in distal colon
*, adjusted for age, sex, race, BMI, diabetes, hypertension, alcohol and smoking. OR, odds ratios; CI, confidence intervals.

any of colonoscopy findings and use of statin in the total
population or in Hispanics
Table 3 shows the demographic characteristics of aspirin
users and non-users. The mean age was higher among
aspirin users than non-users (60.0 vs. 54.9, P<0.0001). There
was no significant difference between the groups in terms
of gender breakdown. Users and non-users also differed in
their racial breakdown (P<0.0001), BMI (P=0.002), presence
of diabetes (P<0.0001) and hypertension (P<0.0001).
Aspirin users and non-users did not differ in any other
factors. Table 4 shows the association between aspirin
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use and colonoscopy findings, adjusted for age, sex, race,
BMI, diabetes, hypertension and smoking or alcohol use.
Compared to non-users of aspirin, those who used aspirin
had an increased risk for having two or more adenomas [odds
ratio (OR) =1.73, 95% CI: 1.00, 2.99, P=0.05] and presence
of an adenoma in the proximal colon (OR =1.66, 95% CI:
1.07, 2.58, P=0.02). No associations were seen between
any other colonoscopy findings and aspirin use in the total
population. There were no significant associations between
aspirin use and colonoscopy findings in Hispanics.
Table 5 shows the demographic characteristics of statin
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Table 3 Demographics of aspirin users and non-users undergoing colonoscopy
Non aspirin user (n=731)

Aspirin user (n=307)

P value*

54.9±10.8

60.0±9.3

<0.0001

367 (50.3%)

151 (49.2%)

0.73

Age
Sex—female
Race (%)
White

202 (27.7)

61 (19.9)

Black

246 (33.7)

152 (49.7)

Hispanic

258 (35.3)

76 (24.8)

24 (3.3)

17 (5.6)

Other
BMI

<0.0001

28.6±5.9

29.8±6.2

0.002

Diabetes—yes

113 (15.5%)

130 (42.4%)

<0.0001

Hypertension—yes

319 (43.6%)

231 (75.2%)

<0.0001

Smoking—yes

197 (27.0%)

93 (30.3%)

0.27

Alcohol—yes

140 (19.2%)

55 (17.9%)

0.64

57 (7.8%)

21 (6.8%)

0.70

Family history of colorectal cancer

*, t-test used for continuous variables and chi square test used for categorical variables. BMI, body mass index.

Table 4 Association between aspirin use and colonoscopy findings in total population and Hispanics
Total population
No aspirin
Adenoma

Aspirin use

Aspirin use vs. no

use (n=731, %) (n=307, %)

use OR (95% CI)*

Hispanics
P value

No aspirin

Aspirin use Aspirin use vs. no

use (n=258, %) (n=76, %)

use OR (95% CI)*

P value

132 (18.1)

76 (24.8)

1.25 (0.87, 1.80)

0.23

34 (13.2)

13 (17.1)

1.56 (0.70, 3.50)

0.28

Adenoma ≥10 mm

17 (2.3)

15 (4.9)

2.03 (0.89, 4.62)

0.09

3 (1.2)

3 (4.0)

6.32 (0.62, 64.25)

0.12

Two or more

39 (5.3)

32 (10.4)

1.73 (1.00, 2.99)

0.05

8 (3.1)

6 (7.9)

2.91 (0.75, 11.24)

0.12

68 (9.3)

51 (16.6)

1.66 (1.07, 2.58)

0.02

19 (7.4)

4 (5.3)

0.68 (0.20, 2.39)

0.55

80 (10.9)

38 (12.4)

0.92 (0.58, 1.47)

0.73

21 (8.1)

10 (13.2)

1.98 (0.78, 5.00)

0.15

59 (8.1)

41 (13.4)

1.55 (0.96, 2.50)

0.07

12 (4.7)

3 (4.0)

0.76 (0.17, 3.37)

0.72

79 (10.8)

35 (11.4)

0.87 (0.54, 1.39)

0.56

22 (8.5)

11 (14.5)

2.23 (0.91, 5.51)

0.08

adenomas
Adenoma present in
proximal colon
Adenoma present in
distal colon
Largest adenoma in
proximal colon
Largest adenoma in
distal colon
*, adjusted for age, sex, race, BMI, diabetes, hypertension, alcohol and smoking. OR, odds ratios; CI, confidence intervals.

and aspirin users and non-users. The mean age was higher
among users of both medications than users of neither
(61.2 vs. 54.1, P<0.0001). There was a difference between
the groups in terms of gender breakdown (P=0.01), racial
breakdown (P=0.04), BMI (P=0.002), presence of diabetes
(P<0.0001) and hypertension (P<0.0001). Medication users
and non-users did not differ in any other factors. Table 6
shows the association between users of both medications
and colonoscopy findings, adjusted for age, sex, race,
BMI, diabetes, hypertension and smoking or alcohol use.
Compared to non-users of either medication, those who used

© Pioneer Bioscience Publishing Company. All rights reserved.

both had an increased risk for having two or more adenomas
(OR =2.56, 95% CI: 1.21, 5.39, P=0.01). No associations
were seen between any other colonoscopy findings
and aspirin use in the total population. In the Hispanic
population, compared to non-users of either medication,
those who used both had an increased risk for having two
or more adenomas (OR =19.04, 95% CI: 1.30, 280.09,
P=0.03), adenoma present in the distal colon (OR =5.75, 95%
CI: 1.64, 20.21, P=0.01) and largest adenoma in distal
colon (OR =5.75, 95% CI: 1.64, 20.21, P=0.01). No other
associations were seen in the Hispanic population.
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Table 5 Demographics of aspirin and statin users and non-users undergoing colonoscopy
Non aspirin and statin user (n=530)
Age

Aspirin and statin user (n=142)

54.1±11.3

P value*

61.2±9.5

<0.0001

244 (46.2%)

82 (57.8%)

0.01

White

156 (29.5)

30 (21.3)

Black

195 (36.9)

68 (48.2)

Hispanic

170 (32.1)

39 (27.7)

Sex—female
Race (%)

Other

8 (1.5)

BMI

4 (2.8)

28.4±6.0

Diabetes—yes

0.04

31.3±6.5

<0.0001

64 (12.1%)

71 (50.0%)

<0.0001

Hypertension—yes

219 (41.3%)

118 (83.1%)

<0.0001

Smoking—yes

155 (29.3%)

36 (25.4%)

0.36

Alcohol—yes

112 (21.1%)

23 (16.2%)

0.19

44 (8.3%)

13 (9.2%)

0.83

Family history of colorectal cancer

*, t-test used for continuous variables and chi square test used for categorical variables. BMI, body mass index.

Table 6 Association between aspirin and statin use and colonoscopy findings in total population and Hispanics
Total population
No statin or

Statin and

aspirin use

aspirin use

Hispanics
No statin or Statin use

OR (95% CI)*

P value

aspirin use

(n=39, %)

OR (95% CI)*

P value

(n=530, %)

(n=142, %)

Adenoma

97 (18.3)

37 (26.1)

1.32 (0.79, 2.21)

0.29

(n=170, %)
23 (13.5)

9 (23.1)

2.55 (0.86, 7.60)

0.09

Adenoma ≥10 mm

15 (2.8)

6 (4.2)

0.95 (0.30, 3.00)

0.93

2 (1.2)

0 (0.0)

N/A

N/A

Two or more

26 (4.9)

19 (13.4)

2.56 (1.21, 5.39)

0.01

3 (1.8)

3 (7.7)

19.04 (1.30,280.09)

0.03

48 (9.1)

25 (17.6)

1.74 (0.94, 3.23)

0.08

11 (6.5)

3 (7.7)

1.09 (0.20, 6.00)

0.92

58 (10.9)

20 (14.1)

1.13 (0.59, 2.14)

0.72

14 (8.2)

8 (20.5)

5.75 (1.64, 20.21)

0.01

46 (8.7)

19 (13.4)

1.27 (0.65, 2.49)

0.49

9 (5.3)

2 (5.1)

0.63 (0.08, 4.94)

0.66

57 (10.8)

19 (13.4)

1.07 (0.56, 2.05)

0.84

14 (8.2)

8 (20.5)

5.75 (1.64, 20.21)

0.01

adenomas
Adenoma present
in proximal colon
Adenoma present
in distal colon
Largest adenoma
in proximal colon
Largest adenoma
in distal colon
*, adjusted for age, sex, race, BMI, diabetes, hypertension, alcohol and smoking. OR, odds ratios; CI, confidence intervals; BMI, body mass index.

Discussion
To our knowledge this is the first study assessing aspirin and
statin use in a Hispanic population. We found that statin use
was not associated with any colonoscopy findings, though
aspirin use increased the risk for two or more adenomas and
adenoma in the proximal colon in our total population, but
did not see the same results when restricting the analysis to
Hispanics. An increased risk for two or more adenomas was
also seen in the total population for users of both statins
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and aspirin. In Hispanics, use of both medications was
associated with two or more adenomas, adenoma present in
the distal colon and largest adenoma in distal colon.
There have been many trials discussing the relationship
between aspirin/non-steroidal anti-inflammatory drugs
(NSAIDs) and colorectal adenoma/carcinomas in
predominant white patient populations. One recent metaanalysis combined four randomized double-blinded placebo
trials that evaluated aspirin and prevention of CRA. The
results showed that aspirin users had a pooled risk ratio of
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0.83 (95% CI: 0.72, 0.96) for any adenoma, with an absolute
risk reduction of 6.7% compared to placebo (6). They
concluded that aspirin is effective for the prevention of
CRA in patients with a history of these lesions. There have
also been studies looking specifically at NSAIDS and colon
cancer. Patients taking 200mg BID of Celecoxib had a
reduced rate of sporadic CRA (RR: 0.67, 95% CI: 0.59, 0.77),
while those taking 400 mg BID also had a reduced risk
of sporadic CRA (RR: 0.55, 95% CI: 0.48, 0.64) (7).
Unfortunately, there are limited randomized trials looking
at non-COX-2 selective NSAIDS. One study showed that
the NSAID, sulindac, reduced the risk of polyp formation
in patients with familial adenomatous polyposis (8).
There are some trials showing that aspirin did not reduce
the incidence of colon cancer and none demonstrating
an association with the presence of adenomas. One study
showed that alternate day 100 mg aspirin did not reduce
the risk of colon cancer (9), while another trial revealed that
aspirin given for five years of duration did not reduce the
risk of colon cancer (10). It is theorized that these trials did
not show risk reduction because of low doses of ASA (11).
Though it is theorized that the mechanism stems from
aspirin/NSAIDs ability to block COX-2 enzymes, which
are expressed in the majority of colonic adenomas and
not in normal colonic tissue, it should be noted that the
mechanism of colon cancer prevention through aspirin/
NSAIDs use is unclear (12).
There have also been many studies looking at the
relationship between statins and colorectal cancer risk.
One case-control study showed that statin use for five years
was associated with a 47 percent relative risk reduction of
colorectal cancer (13). The proposed anti-tumor mechanism
of statins is likely due to a pleiotropic effect on cells. Statins
inhibit HMG-CoA reductase, decreasing cellular levels of
melvonate and result in cells unable to generate products
involved in cell functioning. Statins have also been shown
to induce apoptosis in tumor cells (14). Despite these
findings and proposed mechanism for protection, there are
several studies showing no reduction of colorectal cancer
risk. A meta-analysis including random controlled trials,
cohort, and case control studies with more than 1.5 million
participants, showed no association with statin use and risk
of colorectal cancer. However, sub-group analysis of just
case control studies did show a modest reduction in the risk
of colon cancer (RR: 0.91; 95% CI: 0.87, 0.96) (15).
Statins have also been reported to increase the risk of
adenoma formation with a large prospective randomized
trial demonstrating that statin use increased the risk of
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adenoma formation. However, this was not found among
patients also taking Celebrex, and it was suggested that
the significant antitumor effect Celebrex produces seemed
to counteract the tumor-promoting effect of statins. The
results overall showed that statin use for greater than three
years showed a 40% increase in adenoma detection during
five years of surveillance (RR: 1.39 95% CI: 1.04, 1.86) (16).
Though our study showed increased colonoscopy
findings with statin use, there were several limitations to
the study. Limitations of our study include a retrospective
design and small sample size, particularly in the analysis
looking at combined medication use in Hispanics. Some
of the OR CIs were wide, most likely due to sample size
limitations. Additionally, a further description of Hispanic
immigration also was not defined in our study and Hispanics
can be represented by a diverse ethnic population. There is
always a possibility of selection bias, and that the patients
studied were a population preselected to develop adenomas
while on statins. Another weakness to our study is that
the type of statin used was unknown, as the type of statin
may influence tissue response. Lipophilic statins are more
likely to achieve higher drug levels in nonhepatic tissues,
thus being more likely to alter the biology of colorectal
mucosa than hydrophilic statins (16). Strengths include
a diverse patient population sample representative of the
actual growing US population. Additionally, our analysis
controlled for multiple confounding data that could
influence adenoma detection.
In summary, we have determined that combined aspirin
and statin use, along with the sole use of aspirin, does not
protect against CRA and was associated with their presence
in the Hispanic population. It is unclear why combined
use of aspirin and statin medications was associated with
colonoscopy findings in Hispanics. Our findings may be due
to environmental factors such as dietary, colonic flora, or
genetic susceptibility. Overall, we have demonstrated there
is an association with the presence of CRA and aspirin/
statin use, and our results support further investigation of
this finding in the Hispanic population.
Acknowledgements
Disclosure: The authors declare no conflict of interest.
References
1.

American Cancer Society. Cancer Treatment and
Survivorship Facts & Figures 2012-2013. Atlanta:

www.thejgo.org

J Gastrointest Oncol 2014;5(2):112-118

Davis-Yadley et al. Colorectal adenomas with aspirin and statins

118

2.
3.

4.

5.

6.

7.

8.

9.

American Cancer Society, 2012.
Cho KR, Vogelstein B. Genetic alterations in the
adenoma--carcinoma sequence. Cancer 1992;70:1727-31.
Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic
polypectomy and long-term prevention of colorectalcancer deaths. N Engl J Med 2012;366:687-96.
United States Census Bureau. Profile America Facts for
Features. 30 July, 2013. Available online: www.census.gov/
newsroom/releases/archives/facts_for_features_special_
editions/cb13-ff19.html
Mansouri D, McMillan DC, Roxburgh CS, et al. The
impact of aspirin, statins and ACE-inhibitors on the
presentation of colorectal neoplasia in a colorectal cancer
screening programme. Br J Cancer 2013;109:249-56.
Cole BF, Logan RF, Halabi S, et al. Aspirin for the
chemoprevention of colorectal adenomas: meta-analysis of
the randomized trials. J Natl Cancer Inst 2009;101:256-66.
Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib
for the prevention of sporadic colorectal adenomas. N
Engl J Med 2006;355:873-84.
Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment
of colonic and rectal adenomas with sulindac in familial
adenomatous polyposis. N Engl J Med 1993;328:1313-6.
Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in
the primary prevention of cancer: the Women’s Health Study:

a randomized controlled trial. JAMA 2005;294:47-55.
10. Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin
and incidence of colorectal tumors in a randomized trial. J
Natl Cancer Inst 1993;85:1220-4.
11. Dubé C, Rostom A, Lewin G, et al. The use of aspirin
for primary prevention of colorectal cancer: a systematic
review prepared for the U.S. Preventive Services Task
Force. Ann Intern Med 2007;146:365-75.
12. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of
colorectal cancer in relation to the expression of COX-2.
N Engl J Med 2007;356:2131-42.
13. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the
risk of colorectal cancer. N Engl J Med 2005;352:2184-92.
14. Boudreau DM, Yu O, Johnson J. Statin use and cancer
risk: a comprehensive review. Expert Opin Drug Saf
2010;9:603-21.
15. Bonovas S, Filioussi K, Flordellis CS, et al. Statins and
the risk of colorectal cancer: a meta-analysis of 18 studies
involving more than 1.5 million patients. J Clin Oncol
2007;25:3462-8.
16. Bertagnolli MM, Hsu M, Hawk ET, et al. Statin use
and colorectal adenoma risk: results from the adenoma
prevention with celecoxib trial. Cancer Prev Res (Phila)
2010;3:588-96.

Cite this article as: Davis-Yadley AH, Lipka S, Shen H,
Shah H, Swarup S, Barnowsky A, Silpe J, Mosdale J, Pan
Q, Fridlyand S, Sreeharshan S, Abraham A, Viswanathan P,
Krishnamachari B. Ethnic disparities in the risk of colorectal
adenomas associated with aspirin and statin use: a retrospective
multiethnic study. J Gastrointest Oncol 2014;5(2):112-118. doi:
10.3978/j.issn.2078-6891.2014.010

© Pioneer Bioscience Publishing Company. All rights reserved.

www.thejgo.org

J Gastrointest Oncol 2014;5(2):112-118

